Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18238951 | 0.80 | MEN1 (0.37) | MEN1ALDH1A1GAAKMT2ATRPM5 | |
| SCHEMBL25724458 | 0.77 | LMNA (0.36) | NOS3NOS1NOS2MEN1ALDH1A1 | |
| SCHEMBL26750295 | 0.73 | DYRK1A (0.34) | MEN1ALDH1A1GAAKMT2ATRPM5 | |
| SCHEMBL13558508 | 0.70 | DYRK1A (0.37) | MEN1ALDH1A1GAAKMT2ATRPM5 | |
| SCHEMBL14899837 | 0.69 | DYRK1A (0.41) | NOS3NOS1NOS2MEN1ALDH1A1 | |
| SCHEMBL13557976 | 0.67 | DYRK1A (0.35) | MEN1ALDH1A1GAAKMT2ATRPM5 | |
| SCHEMBL20631803 | 0.66 | MEN1 (0.40) | MEN1ALDH1A1GAAKMT2ATRPM5 | |
| SCHEMBL20631795 | 0.66 | LMNA (0.38) | MEN1ALDH1A1GAAKMT2ATRPM5 | |
| SCHEMBL941915 | 0.65 | CHRNB2 (0.48) | MEN1ALDH1A1GAAKMT2ATRPM5 | |
| SCHEMBL9118230 | 0.64 | DYRK1A (0.40) | MEN1ALDH1A1GAAKMT2ATRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ERBB2, ERBB3, BRCA1 | NOS3 4680/4885NOS1 4794/4885NOS2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.